What the business is, and whether it's a good one at a fair price.
Manufactures active pharmaceutical ingredients (APIs), finished formulations and biologics, with capabilities spanning complex oncology and non-oncology chemicals, peptides, transdermal patches, biosimilars and antibody-drug conjugates (ADCs). Within formulations, three U.S. 505(b)(2) products are approved and growing; NorUDCA was launched in India during FY26; Rotigotine is set for a European launch in FY27; Abraxane exhibit batches are complete for a planned FY28 launch; and Enzalutamide is targeted for FY27 filing. The biologics stream is running Aflibercept Phase III for an FY27 India launch, has two NBE programs entering Phase I in FY27, and has commissioned an integrated ADC manufacturing suite. A co-development and supply agreement with Orion Corporation covers an intravenous Nivolumab biosimilar for Europe. The CDMO pipeline includes three U.S. NCE programs — the first launched by a partner in Q4 FY26, a second in Phase III, and a Unicycive program awaiting FY27 approval — with licensing income management expects to remain around INR 200 crore in FY27. The Europe formulation business crossed INR 200 crore in FY26 with over 100% year-on-year growth. The biggest cost is raw materials at 30.6% of revenue, followed by employees at 21.8%, other operating expenses at 20.1%, depreciation at 7.8% and capex at 24.1% of revenue. FY26 capex of INR 361 crore was funded by internal accruals, leaving net debt at INR 613 crore.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from SHILPA MEDICARE LTD's filed financials and exchange disclosures
SHILPA MEDICARE LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SHILPAMED.
Yes. Over the trailing twelve months SHILPA MEDICARE LTD reported a net profit of ₹297 Cr on revenue of ₹1,682 Cr.
Yes. The dividend yield is 0.05% at the current price. It paid out 4% of its profit as dividend in FY26.
No. Debt stands at 0.25× equity, and it carries net debt of ₹617 Cr. That is lower than 35% of its 171 Pharmaceuticals peers.
On trailing P/E, SHILPA MEDICARE LTD ranks 143 of 169 in Pharmaceuticals — cheaper than 16% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session SHILPA MEDICARE LTD moves 1.43% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by SHILPA MEDICARE LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
